Executive summary
US Drug Patent 8,598,119 is a US method-of-use and compound-parameter estate focused on a 5-HT2A-selective receptor blocker defined by Formula I (with specified X and Y substituents), used for 5-HT2A-related disorders including psychosis, schizophrenia, depression, sleep disorders (including sleep maintenance insomnia), and dyskinesia (including levodopa-induced dyskinesia). The claim set also hard-codes a key pharmacologic selectivity concept for sleep: block 5-HT2A while not blocking, or minimally blocking, dopamine D2. The independent claim spans broad patient populations and add-on regimens, while dependent claims narrow to specific indications, patient tolerability criteria, and dose ranges (notably 0.5–10 mg, 2.5–5 mg, and <5 mg / <2.5 mg) that can drive both design-around and litigation outcomes.
Important limitation for enforceability scope: with only the claim text provided, this analysis focuses on what the claims cover and how they typically translate into infringement and licensing risk. It does not map to the full spec disclosure, prosecution history, or enablement for the specific “Compound of Formula I” embodiment because those are not provided.
US Patent 8,598,119 scope: what claims cover for 5-HT2A-related disorders and Formula I
Bottom line: The patent covers methods of treating disorders using a Formula I compound administered in a dose that selectively blocks 5-HT2A, with additional narrowing tied to (i) disorder subtype, (ii) patient selection, (iii) dose band, and (iv) D2 sparing for sleep indications.
What is the claimed active requirement?
The method administers a “Compound of Formula I” defined by substituent constraints:
- X is O, —NH, or —N(CH3)
- Y is —O— or —C(O)—
- Delivered in free or pharmaceutically acceptable salt form
- Administered in a dose which selectively blocks the 5-HT2A receptor
This is a classic functional-parameter compound limitation: the compound must be of Formula I and the dose must achieve the 5-HT2A selectivity described.
What diseases are expressly covered?
Claim 1 broadly captures “one or more 5-HT2A-related disorders,” then dependent claims name concrete indications:
- Psychosis (claim 2)
- Schizophrenia (claim 3)
- Depression (claim 4)
- Sleep disorders (claims 8–11), including:
- Sleep disorder where patient has depression (claim 8)
- Sleep disorder where patient has psychosis (claim 9)
- Sleep disorder where patient has Parkinson’s disease (claim 10)
- Sleep disorder where patient has depression and psychosis or Parkinson’s disease (claim 11)
- Sleep maintenance insomnia (claim 17)
- Insomnia in depression patients (claim 24)
- Dyskinesia (claim 12), specifically:
- Levodopa-induced dyskinesia in Parkinson’s (claim 13)
What patient-comorbidity and tolerability gates exist?
- Claim 5 covers patients unable to tolerate side effects of conventional antipsychotic drugs.
- Claim 6 specifies those conventional antipsychotics as a list: haloperidol, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone.
- Claim 7 ties depression to patients with psychosis or Parkinson’s disease.
These dependent claims matter in both infringement pleading and design-around because they create additional factual predicates beyond generic “treat depression.”
What does claim 16 add: D2 sparing requirement for sleep indications
Bottom line: Claim 16 is narrower than claim 1. It targets sleep disorders with a selectivity statement that explicitly limits dopamine D2 effects.
Claim 16’s pharmacologic selectivity constraint
For sleep disorders, the Compound of Formula I must be dosed to:
a) block 5-HT2A (required)
b) either does not block, or minimally blocks, dopamine D2 (limitation)
This converts the earlier “selectively blocks 5-HT2A” theme into a two-receptor selection rule for sleep.
Sleep disorder definition in dependent claims
- Sleep maintenance insomnia (claim 17)
- Insomnia in a depression patient (claim 24)
- Broader sleep disorder commingled with comorbid states in claims 8–11 (linked to claim 1 base, not claim 16 base)
Practical infringement consequence of the D2 limitation
A challenger can try to argue:
- dosing achieves 5-HT2A blockade but still produces meaningful D2 blockade, taking it outside claim 16; or
- the “minimally blocks” threshold is not met.
Conversely, enforceability arguments often use receptor binding/functional assay data and clinical biomarker proxies to show D2 sparing at relevant exposure.
How do the dose range claims restrict the method coverage? (0.5–10 mg, <5 mg, <2.5 mg)
Bottom line: Several dependent claims set dose bands. These ranges are a key lever for both licensing and design-around.
Dose band dependent claims (claim 16 platform)
- 0.5–10 mg (claim 20)
- 2.5–5 mg (claim 21)
- <5 mg (claim 22)
- <2.5 mg (claim 23)
Broader dose framing
- From 2.5 mg to 50 mg (claim 28)
- Additional structure/dose claim lines appear (claims 27 and 29) but the text you provided is incomplete for those sections.
Practical reading
- The independent method claim (claim 1) includes “selectively blocks 5-HT2A,” but does not specify a numeric dose.
- Dependent claims can be used to argue infringement for specific marketed dose regimens and can also increase licensing leverage if a competitor’s label dose sits within these ranges.
What formulations and structures are protected: salts, Formula I embodiments, and “structure” claims
Bottom line: Protection is tied to the specific structural class (Formula I substitutions) plus free/salt forms, and dependent “structure” claims indicate specific embodiments.
Free and pharmaceutically acceptable salts
Claim 1 explicitly covers:
- free compound
- pharmaceutically acceptable salt form
This typically broadens coverage to any salt form meeting the same active formula definition, assuming salt switching does not move you outside Formula I.
Formula claim constraints (X and Y)
The substituent sets for X and Y are the most enforceable structure-defining elements you supplied:
- X = O or —NH or —N(CH3)
- Y = —O— or —C(O)—
Structure-dependent claims (incomplete in provided text)
You provided claim 27 as “wherein the compound of Formula I has the structure:” but did not paste the structure. Claim 29 similarly is incomplete. Those dependent “structure” clauses often anchor the narrowest embodiment(s) and can be used in claim charting if the marketed compound matches the depicted scaffold.
What is the breadth of combination therapy: are add-on antipsychotics, anxiolytics, and antidepressants inside the claims?
Bottom line: Claims 14–15 and 18–19 create broad “further comprising” add-on therapy lists. That can expand infringement risk to combination labeling and prescribing patterns.
Combination therapy list in claim 14 (beyond claim 1)
Claim 14 allows add-on agents including broad categories and specific actives, such as:
- GABA activity modulators and GABAB agonist
- melatonin agonist
- ion channel modulator
- SARIs
- orexin receptor antagonist
- H3 agonist
- noradrenergic antagonist
- galanin agonist, CRH antagonist
- growth hormone / agonists
- estrogen / agonists
- neurokinin-1 drugs
- antidepressants and antipsychotics
Claim 15 then provides an extremely long specific list of small molecules that includes:
- “awake/sleep” drugs: modafinil, armodafinil
- anxiolytics/benzodiazepines: alprazolam, lorazepam, diazepam, etc.
- hypnotics: zopiclone, eszopiclone, zaleplon, zolpidem
- multiple antidepressants: SSRIs/SNRIs and older agents
- multiple antipsychotics: risperidone, clozapine, aripiprazole, olanzapine, quetiapine, ziprasidone, paliperidone
- investigational/other receptor drugs named in the list (e.g., eplivanserin, pruvanserin, volinanserin, sarizotan, repinotan)
Combination therapy list in claim 18 (claim 16 platform)
Claim 18 mirrors claim 14 category breadth for sleep methods.
Claim 19 mirrors claim 15’s long drug list for add-on therapy in sleep contexts.
Infringement impact of “further comprising”
A “further comprising” clause typically means:
- the accused activity is still infringement if the Formula I compound is administered as recited,
- even if the patient simultaneously receives other therapies from the list.
For litigation, this can reduce defenses like “we don’t claim the other drugs are required.” For certification and label design, it increases the importance of how the product is marketed and co-prescribed.
How are Parkinson’s disease and levodopa-related dyskinesia handled?
Bottom line: Parkinson’s appears both as a comorbidity for sleep (claims 10–11) and as a dyskinesia indication (claim 13), plus an add-on therapeutic list expressly includes Parkinson’s regimen drugs.
Express indications
- Sleep disorders in Parkinson’s patients (claims 10 and 11)
- Levodopa-induced dyskinesia in Parkinson’s (claim 13)
Parkinson’s add-on therapies included
Claims 25–26 add a list including:
- L-dopa, co-careldopa
- duodopa, stalova, symmetrel
- benzotropine, biperiden
- bromocryiptine
- entacapone, pergolide
- pramipexole, procyclidine, ropinirole
- selegiline, tolcapone
This expands “further comprising” coverage such that patients on standard Parkinson’s regimens are likely within the dependent-claim framework if Formula I is administered for the claimed purposes.
What competitor products would create the highest infringement risk under this claim set?
Bottom line: Risk concentrates on compounds that (i) fall within Formula I’s X/Y substituent constraints, (ii) achieve 5-HT2A blockade at clinically used doses, and (iii) for sleep, show D2 minimal blockade at exposure levels consistent with dosing bands.
High-risk fact patterns
- A marketed 5-HT2A antagonist with D2 sparing characteristics used for insomnia or sleep maintenance insomnia.
- A compound used for psychosis/schizophrenia/depression where dosing aligns with dependent dose claims, especially if it also has D2-friendly selectivity.
- A Formula I compound co-prescribed with drugs on the “further comprising” list (common in psychiatric and sleep practice).
How generic or “me-too” molecules could attempt to design around
- Change the scaffold to fall outside Formula I by altering X or Y (most direct structural carve-out).
- Increase D2 blockade to avoid claim 16’s “does not block or minimally blocks D2” condition for sleep methods.
- Market/use at doses outside the dependent dose bands, while still arguing the independent claim requires only “selectively blocks 5-HT2A.” Practically, this requires both pharmacology and label alignment.
Claim construction fault lines: where disputes are most likely
Bottom line: The claim language includes functional receptor selectivity terms and dose-to-receptor performance constraints, which typically produce expert-heavy disputes.
“selectively blocks the 5-HT2A receptor”
Key issues in claim charting:
- whether selectivity is measured by binding affinity (Ki/Kd), functional assay (EC50/IC50), or clinical exposure proxies.
- what level of selectivity qualifies (not numerically defined in the text you provided).
“either does not block, or minimally blocks, dopamine D2”
This is more specific than the generic selectivity language but still uses a relative standard (“minimally blocks”) that may require:
- a threshold definition,
- assay method consistency,
- dose-exposure mapping.
“in a dose which selectively blocks the 5-HT2A receptor”
Dose is both a quantity and a receptor effect. Parties will fight over exposure and receptor engagement.
“sleep disorder” scope
Claims 8–11 are broad “sleep disorder” tied to comorbid conditions. Claim 16 and claim 17/24 narrow to insomnia constructs. That gives multiple pathways for infringement allegations depending on clinical use.
Competitive landscape and licensing posture: what this patent signals
Bottom line: The claim set targets a specific therapeutic strategy: 5-HT2A modulation with reduced D2 liabilities, used across psychiatric and sleep indications, including Parkinson’s-related syndromes.
Why this matters commercially
- Many antipsychotics hit both 5-HT2A and D2. Claim 16’s D2 sparing makes it particularly aimed at atypical profiles and could be leveraged against D2-involving regimens for insomnia.
- The broad “further comprising” drug list aligns with real-world prescribing, reducing gaps between monotherapy and combination therapy.
Likely licensing triggers
- Any company developing a 5-HT2A selective blocker for insomnia that has measurable D2 effects could face:
- risk of infringement assertions under claim 16 and dependent dose claims (20–23),
- a settlement pressure point if its clinical dose overlaps the claimed bands.
Key takeaways
- US 8,598,119 is a Formula I + functional selectivity patent: administer a compound defined by X (O/—NH/—N(CH3)) and Y (—O—/—C(O)—) in a dose that selectively blocks 5-HT2A.
- The estate covers psychosis, schizophrenia, depression, and sleep disorders, including sleep maintenance insomnia and depression-linked insomnia, plus dyskinesia including levodopa-induced dyskinesia.
- Claim 16 adds a hard pharmacology gate for sleep: block 5-HT2A while not blocking or minimally blocking D2.
- The dependent claims add dose bands (notably 0.5–10 mg, 2.5–5 mg, and thresholds <5 mg / <2.5 mg) that can drive the commercial “landing zone” for infringement.
- “Further comprising” clauses include broad lists of antipsychotics, antidepressants, hypnotics, anxiolytics, and Parkinson’s regimens, expanding risk beyond monotherapy.
- Litigation is likely to hinge on receptor engagement metrics (assay method, thresholding, exposure-response) and on proving the accused regimen meets the D2 minimal blockade standard for sleep.
FAQs
-
Does claim 1 require evidence that the patient is diagnosed with a named condition?
Claim 1 covers “one or more 5-HT2A-related disorders,” and dependent claims specify conditions like psychosis, schizophrenia, depression, sleep disorders, and dyskinesia. Coverage for named disorders is explicit in dependents; the independent hinges on whether the disorder qualifies as 5-HT2A-related and is treated as such.
-
What is the most direct design-around for claim 16?
Avoid a compound or regimen that achieves 5-HT2A blockade without also producing meaningful D2 blockade. Because claim 16 includes a D2 “does not block or minimally blocks” limitation, D2 engagement is the primary avoidance lever for sleep methods.
-
Are combination therapies part of the claimed method?
The claims include “further comprising” additional agents from broad categories and extensive enumerated drug lists. Infringement risk increases if clinical use or label-supported regimens include these agents alongside the Formula I compound.
-
Do the dose claims create separate patent rights or just narrow claim scope?
Dependent dose claims narrow the method scope to specific dosage ranges (including thresholds). They can still support infringement where a marketed regimen fits those ranges, but they do not replace the broader independent coverage.
-
Is Parkinson’s disease limited to dyskinesia or also included for sleep?
It is included for both: Parkinson’s appears in sleep disorder comorbidities (claims 10–11) and explicitly as levodopa-induced dyskinesia (claim 13), plus Parkinson’s regimen drugs are listed in the “further comprising” sections (claims 25–26).
References
- United States Patent Application / Patent No. 8,598,119. (Claims text provided in prompt).
